IL6 and arthritic joint disease: Given that both IL-6 and IL-17 are involved in arthritis-induced hyperalgesia [32–34] and administration of a macrophage blocker reduced hyperalgesia [35], the reduced M1 macrophage number and IL-6 and IL-17 levels we showed may have synergistically contributed to a decline in chronic hyperalgesia and arthritis score.